Biopharmaceutical company Pharming Group N.V. (Euronext Amsterdam:PHARM) (NASDAQ:PHAR) revealed on Wednesday that it has received a positive final recommendation from the National Institute for Health and Care Excellence (NICE) for Joenja (leniolisib) as a treatment for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).
The recommendation covers adult and paediatric patients aged 12 and over within the National Health Service (NHS) in England and Wales, making Joenja the first and only APDS-specific treatment to be reimbursed by the NHS.
NICE based its decision on data from a Phase III trial demonstrating significant improvements in immune function and disease control in patients treated with leniolisib, a selective oral PI3Kδ inhibitor.
These outcomes were sustained in an open-label extension study, reinforcing leniolisib's long-term clinical benefit for this rare and progressive immunodeficiency.
The recommendation aligns with the UK Medicines and Healthcare products Regulatory Authority approval and is issued under NICE's Highly Specialised Technologies pathway.
Joenja is now reimbursed in England through the Innovative Medicines Fund, providing immediate access to eligible patients. In Wales, funding is expected within three months through NHS specialist centres.
Cinclus Pharma signs EUR220m European commercialisation deal with Zentiva for acid reflux therapy
Sanofi to acquire Vigil Neuroscience for USD470m to expand Alzheimer's pipeline
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
Revalesio reports further analysis from Phase 2 RNS60 trial for acute ischemic stroke treatment
AnnJi reports positive Phase 1/2a results in Spinal and Bulbar Muscular Atrophy trial
Sarepta receives UK approval to continue dosing in ELEVIDYS ENVISION study
MSD expands clinical development of Orion's opevesostat to include women's cancers
Promontory Therapeutics reports successful FDA meeting after Phase 2 study of PT-112
Trevi Therapeutics reports additional results from Phase 2a RIVER trial of Haduvio
Accropeutics reports positive data from Phase 2 psoriasis treatment trial
NextCell Pharma partners with Fujifilm Irvine Scientific to deliver integrated MSC solutions
Lifecare files for first human trial of glucose monitoring implant, targeting CE-mark
EXACT Therapeutics reports strong Phase 1 results for ACTIVATE trial in colorectal liver metastases